HB2934, the STATES 2.0 Act, would substantially revise how federal law applies to marijuana by creating a new rule that generally removes compliant state- and tribal-licensed marijuana activity from the reach of the Controlled Substances Act. Under the bill, marijuana manufactured, possessed, distributed, or otherwise handled in compliance with state law would no longer be treated as federally illegal, and the same general protection would extend to federally recognized Indian tribes operating within their jurisdiction, so long as the relevant state also permits marijuana activity. The bill also protects interstate transportation of marijuana between states that allow it, while preserving state authority to impose reasonable time, place, and manner restrictions and public-health protections.
The bill also directs federal agencies to build a regulatory framework for marijuana products. It would require the Attorney General to finalize a rule treating compliant marijuana as a substance not included in any federal schedule, and it would assign the Food and Drug Administration authority over marijuana products that qualify as drugs, foods, dietary supplements, or cosmetics. For other marijuana products, HHS would have to issue regulations within 180 days covering contaminant testing, manufacturing practices, marketing, and post-market reporting, with special attention to youth prevention, but without requiring premarket approval. The bill further excludes compliant marijuana conduct from certain federal trafficking, forfeiture, and tax provisions, including the Internal Revenue Code’s section 280E.
HB2934 would also amend transportation and age-related provisions of the Controlled Substances Act to carve out compliant marijuana activity from certain federal offenses, including transportation safety offenses and some distribution restrictions. It would allow medicinal marijuana distribution to persons under 21 in compliance with the new federal-state framework, and it would bar marketing marijuana products in combination with alcohol, tobacco, drugs, devices, or biological products. In addition, the bill requires the Comptroller General to study the effects of marijuana legalization on traffic safety and report to Congress within one year.
The overall sentiment reflected in the bill text is strongly supportive of state-led marijuana legalization and regulation, with an emphasis on reducing illicit markets, improving consumer safety, and respecting tribal self-determination. The findings argue that current federal restrictions create punitive tax and enforcement structures that disadvantage legal businesses and sustain illegal sales, while legalization can free law-enforcement resources for more serious crime. Because there are no committee transcripts or recorded votes provided, there is no documented opposition or amendment debate in the supplied materials.
The main points of contention inherent in the bill are likely to be federalism, interstate commerce, public safety, youth access, and the scope of FDA and DOJ authority over marijuana products. The bill attempts to balance legalization with restrictions on underage involvement, product safety, and interstate shipment, but it still raises questions about how states with prohibitions would be affected, how federal enforcement would work in practice, and whether the proposed regulatory and tax framework would adequately address impaired driving, diversion, and public-health concerns.
The bill would significantly narrow the application of the Controlled Substances Act to marijuana by exempting compliant state and tribal marijuana activity from federal prohibition, creating a federal non-scheduling rule for such conduct, and limiting related trafficking, forfeiture, and tax consequences. It would also require new federal regulations from DOJ and HHS/FDA, authorize interstate transport between legal jurisdictions, and direct a federal study on marijuana-related traffic safety, thereby shifting marijuana policy toward a state-regulated, federally supervised model.
The bill’s stated purpose and findings reflect a favorable view of marijuana legalization and state autonomy, with support for legal markets, tribal sovereignty, consumer protections, and reduced illicit activity. The absence of recorded votes or committee testimony means there is no documented formal opposition in the provided materials, but the structure of the bill suggests it is designed to appeal to both legalization advocates and lawmakers concerned with regulation, safety, and enforcement.
Likely areas of contention include whether federal law should defer to state marijuana regimes, how to handle interstate transport through prohibition states, and whether the bill sufficiently protects public health and youth access. Critics may also question the FDA’s role, the adequacy of the proposed tax and regulatory framework, and the bill’s treatment of impaired driving and marijuana products marketed alongside alcohol or tobacco. Supporters are likely to emphasize state rights, tribal self-determination, and the reduction of illicit markets and enforcement burdens.